Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Vancouver, Canada, April 08, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today the publication of an international patent application in collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). The patent application covers innovative psychedelic-based compounds designed for the treatment of mental health disorders and addiction.

Read more at globenewswire.com